There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind others such as oncology, wherein, rather than using 'biomarker' as a blanket term for a diverse range of clinical phenomena, biomarkers have been actively classified into separate categories, including prognostic and predictive tests. A similar taxonomy is proposed for neuropsychiatric diseases in which the core biology remains relatively unknown. This paper divides potential biomarkers into those of (1) risk, (2) diagnosis/trait, (3) state or acuity, (4) stage, (5) treatment response and (6) prognosis, and provides illustrative exemplars. Of course, biomarkers rely on available technology and, as we learn more about the neurobiological correlates of neuropsychiatric disorders, we will realize that the classification of biomarkers across these six categories can change, and some markers may fit into more than one category.
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BIOMARKERS OF RISK
A biomarker of risk offers a quantitative index of the extent to which an individual is predisposed to developing a disorder. It should be capable of being applied to asymptomatic individuals to allow characterization of their risk of developing disease, implying an intervention target. Oestrogen-mediated epigenetic DNA methylation patterns in pregnant women at risk for post-partum depression showed predictive capacity, 1 potentially providing an early screening test for risk. With increasing sample size, informative genomic risk profile scores are becoming available. 2 
DIAGNOSTIC OR TRAIT BIOMARKERS
A diagnostic biomarker is a measurable characteristic that reflects the presence of a disease state. To be of diagnostic utility, a biomarker must ideally have sufficient sensitivity and specificity to allow it to characterize one disorder alone, and should ideally display little or no overlap with any other neuropsychiatric disease ( Table 1) . Arguably the best current diagnostic biomarker are senile plaques and neurofibrillary tangles seen in Alzheimer's Disease (AD). In essence senile plaques and neurofibrillary tangles conform to the specifications of a diagnostic biomarker; however, given they can only be confirmed post-mortem, they are impractical for clinical use. The use of multiplex molecular profiling approaches capturing proteins and small molecules has shown potential, differentiating those with schizophrenia from controls. 3 
STATE OR ACUITY BIOMARKERS
A biomarker of state is a measurable characteristic that reflects the severity of a particular disease process. Kapczinski et al. 4 defined a systemic toxicity index complied using aggregates of neurotrophins (neurotrophin-3, brain-derived neurotrophic factor ), inflammatory markers (interleukin-6, tumour necrosis factor-α and interleukin-10) and oxidative stress markers (protein carbonyl content, total reactive antioxidant potentials, thiobarbituric acid reactive substances). This differentiated people with bipolar disorder in acute episodes of mania and depression from euthymia. The potential state biomarkers of psychosis were demonstrated using a convergent functional genomics approach, finding several candidate biomarkers with differential expression in both delusional and high hallucinatory states. Serum brainderived neurotrophic factor levels in major depressive disorder , schizophrenia and bipolar disorder are further exemplars, being reduced relative to controls, with such reduction correlating with clinical severity. 5
STAGE BIOMARKERS
The major neuropsychiatric disorders are increasingly conceptualized as potentially progressive illnesses. A biomarker of stage, reflecting extant classifications of staging, would allow categorization of an individual's present stage of illness. Potential staging biomarkers include amyloidβ1-42, tau and phospho-tau 181 proteins obtained from the cerebro-spinal fluid of patients with mild cognitive impairment; alterations of cerebro-spinal fluid amyloidβ1-42, tau and phosphor-tau were present in mild cognitive impairment patients and those with early dementia stages, but not in mild cognitive impairment patients who were not at increased risk of developing Alzheimer's disease. 6 Cellular correlations of neuroprogression are also reflected in white blood cell telomere length. Shorter telomeres, representative of accelerated ageing, are increased in mood disorders and are associated with lifetime number of depressive episodes, but not with illness duration. 7
TREATMENT RESPONSE BIOMARKERS
A biomarker of response would index the probability of response to a given treatment, and would ideally allow clinicians to stratify patients to effective and personalized treatments, which would be more likely to work for an individual patient. Illustrating the caveat that biomarkers can overlap between categories, elevated levels of cytokines appear to be predictive for the antidepressant effects of exercise. 8 Depressed individuals, who had lower telomerase activity before treatment and showed a larger increase in telomerase activity with treatment, had better antidepressant responses. Single-nucleotide polymorphism variants of glutamate decarboxylase-like protein 1 might be associated with the response of individuals with bipolar 1 disorder to lithium therapy; two particular single-nucleotide polymorphisms had a sensitivity of 93% for predicting lithium response. 9 
PROGNOSTIC BIOMARKERS
A biomarker of prognosis would predict the likely course and outcome of an illness. Having prognostic information would allow clinicians to tailor their therapeutic options effectively and select a more appropriate treatment for an individual given the likely curve of their future illness arc. The presence of white matter lesions predicts a worse course and outcome and poorer treatment response in depressive disorder. In patients with major depressive disorder, people with higher levels of tumour necrosis factor-α and interleukin-6 have a poorer response to antidepressant therapy and greater treatment resistance. 10 Psychiatric diagnoses currently do not adequately reflect the underlying aetiopathogenesis. There remains a pressing need to establish reliable biomarkers to help in the categorization, personalized treatment prediction and prognostication of the major neuropsychiatric disorders. Having a clearer taxonomy of biomarkers will help us appreciate how these tests reflect aetiopathogenesis and assist us in pinning down the risk and progression of the underlying neurobiological correlates of such diseases. A measurable characteristic that reflects the severity of a particular disease process, which delineates the present acuity and severity of an individual disease episode 4. Biomarkers of stage A measurable characteristic reflecting extant classifications of staging, which indicates an individual's stage of illness 5. Biomarkers of treatment response A measurable characteristic capable of indexing the probability of response to a given treatment to potentially assist clinicians in selecting therapeutic options for an individual patient 6. Biomarkers of prognosis A measurable characteristic that could predict the likely course and outcome of an illness Towards a classification of biomarkers J Davis et al
